Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...

The S&P/ASX 200 fell 3% in December as Santa rally failed to eventuate yet again. But… it wasn't ALL bad, as these 50 stocks ...

ASX tech rocked a 50pc gain in 2024, Archer Materials shone in December, and Dubber and Brainchip have cashed in on major ...

Ads for AI-related roles are shrinking in Australia, new job data reveals, with the number down 35 per cent compared to over ...

Neurizon recently received EMA orphan designation for NUZ-001 to treat ALS and filed an FDA IND application to begin a phase ...

Aussies are missing out on hundreds of thousands of dollars in superannuation returns, according to one of the nation’s largest super funds.

Stockhead delves into Elevate Uranium, a company advancing its uranium assets in Namibia, utilising its patented U-pgrade process.

Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a ...

Morningstar’s analyst picks ResMed and PWR as top ASX long-term plays, with ResMed eyeing sleep market domination.

With pending news flow of significance coming in 2025, these ASX-listed gas companies could be worth putting on your radar.

Percheron Therapeutics' board of directors has written a letter to shareholders following failure of its phase 2b trial.